Comparison of the Effect Between Levofloxacin and Moxifloxacin Among MDR-TB Patients

Comparison of the Effect Between Levofloxacin and Moxifloxacin on the Culture Conversion After 3 Months Treatment Among MDR-TB Patients; Prospective Multicenter Randomized Open Label Phase III Trial

Fluoroquinolone is a one of the most important drugs for treatment of multidrug-resistant TB (MDR-TB). Among them, levofloxacin and moxifloxacin has been used most widely. However, there is no study to directly compare the efficacy of levofloxacin and moxifloxacin among MDR-TB patients. The investigators will compare the efficacy of levofloxacin and moxifloxacin through a prospective multicenter randomized open label phase III trial.

Inclusion Criteria:

• Patients with multidrug-resistant TB, but sensitive to levofloxacin and moxifloxacin

Exclusion Criteria:

• Achieved negative conversion of M. TB culture before the enrollment
• Positive anti-HIV antibody
• Pregnant women or sexually active women without using proper birth control method
• Serum creatine grater than 2mg/dL, or urine protein greater than 2+
• Serum total bilirubin greater than 2 mg/dL or AST and ALT greater than 1.5 times of normal upper limit
• History or current arrhythmia
• Hypersensitivity to levofloxacin, moxifloxacin,or rifabutin
• Should use drug containing metal-ion, warfarin, phenytoin, theophylline, probenecid regularly